Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Interleukin-1 receptor-associated kinase 4 | ||
Ligand | BDBM639281 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | IRAK4 ADP-Glo Assay | ||
IC50 | 3.20±n/a nM | ||
Citation | Chen, Y; Masuda, E; Lamagna, C BICYCLIC INHIBITORS OF IRAK US Patent US20230391748 Publication Date 12/7/2023 | ||
More Info.: | Get all data from this article, Assay Method | ||
Interleukin-1 receptor-associated kinase 4 | |||
Name: | Interleukin-1 receptor-associated kinase 4 | ||
Synonyms: | IRAK-4 | IRAK4 | IRAK4_HUMAN | Interleukin-1 receptor-associated kinase 4 (IRAK-4) | Interleukin-1 receptor-associated kinase 4 (IRAK4) | Renal carcinoma antigen NY-REN-64 | ||
Type: | Protein | ||
Mol. Mass.: | 51519.08 | ||
Organism: | Homo sapiens (Human) | ||
Description: | Q9NWZ3 | ||
Residue: | 460 | ||
Sequence: |
| ||
BDBM639281 | |||
n/a | |||
Name | BDBM639281 | ||
Synonyms: | 1-(((R)-1-(2-cyanoacetyl)piperidin-3-yl)oxy)-4-((cis-3-(dimethylamino)cyclobutyl)ethynyl)-7-isopropoxyisoquinoline-6-carboxamide | US20230391748, Compound I-106 | ||
Type | Small organic molecule | ||
Emp. Form. | C29H35N5O4 | ||
Mol. Mass. | 517.6193 | ||
SMILES | CC(C)Oc1cc2c(O[C@@H]3CCCN(C3)C(=O)CC#N)ncc(C#C[C@H]3C[C@H](C3)N(C)C)c2cc1C(N)=O |r,wU:9.8,25.25,27.30,(3.4,5.33,;2.63,4,;3.4,2.67,;1.09,4,;.32,2.67,;1.09,1.33,;.32,,;1.09,-1.33,;2.63,-1.33,;3.4,-2.67,;2.63,-4,;3.4,-5.33,;4.94,-5.33,;5.71,-4,;4.94,-2.67,;7.25,-4,;8.02,-2.67,;8.02,-5.33,;9.56,-5.33,;11.1,-5.33,;.32,-2.67,;-1.22,-2.67,;-1.99,-1.33,;-3.53,-1.33,;-5.07,-1.33,;-6.61,-1.33,;-7.7,-2.42,;-8.79,-1.33,;-7.7,-.24,;-10.33,-1.33,;-11.1,-2.67,;-11.1,,;-1.22,,;-1.99,1.33,;-1.22,2.67,;-1.99,4,;-1.22,5.33,;-3.53,4,)| | ||
Structure |